Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data

Infectious Diseases and Therapy
Johannes BeeslaarJohn L Perez

Abstract

An extensive clinical development program showed that the meningococcal serogroup B-factor H binding protein (MenB-FHbp) vaccine affords protection against MenB disease for adolescents and adults. Data were pooled from multiple studies within the program to examine whether MenB-FHbp immunogenicity was influenced by sex, age, or race. Immunogenicity was assessed in subjects from seven studies who received 120 µg MenB-FHbp (at 0, 2, 6 months) and had evaluated immune responses against four representative test strains via serum bactericidal assays using human complement (hSBAs). Immune responses were presented by sex (male, female), age group (10-14, 15-18, 19-25, 10-25 years), and race (white, black, Asian, other). Among 8026 subjects aged 10-25 years included in this analysis, MenB-FHbp elicited robust immune responses in a high percentage of subjects regardless of demographic characteristics. Across all test strains and demographic subsets, a ≥ 4-fold rise in titer from baseline was achieved in 76.7-95.0% of subjects, with no major differences by sex, age groups assessed, or races evaluated. Corresponding percentages achieving titers ≥ the lower limit of quantification (LLOQ) against all four strains combined were 79.7-87.3% (s...Continue Reading

References

Jun 1, 1969·The Journal of Experimental Medicine·I GoldschneiderM S Artenstein
Sep 11, 2004·Clinical and Diagnostic Laboratory Immunology·Bracha Rager-ZismanDiane E Griffin
Feb 16, 2007·The New England Journal of Medicine·Robert B BelsheUNKNOWN CAIV-T Comparative Efficacy Study Group
May 29, 2007·The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine·Court PedersenUNKNOWN HPV Vaccine Adolescent Study Investigators Network
Dec 10, 2008·Archives of Internal Medicine·Renata J M EnglerUNKNOWN Walter Reed Health Care System Influenza Vaccine Consortium
Dec 18, 2008·European Journal of Immunology·Alicia Demirjian, Ofer Levy
Sep 25, 2009·The New England Journal of Medicine·Arnold S MontoJohn C Victor
Apr 27, 2010·The Lancet Infectious Diseases·Sabra L KleinAndrew Pekosz
Oct 29, 2010·Journal of Translational Medicine·Luciano Mariani, Aldo Venuti
Apr 16, 2013·Human Vaccines & Immunotherapeutics·Janet M Lord
Apr 22, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Juventila LikoPaul R Cieslak
Jun 15, 2014·Cancer Causes & Control : CCC·Adriana C VidalCathrine Hoyo
Jan 13, 2015·Transactions of the Royal Society of Tropical Medicine and Hygiene·Sabra L KleinEleanor N Fish
Feb 12, 2015·Cellular Immunology·Trine N Jørgensen
Aug 13, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Cornelis H van WerkhovenMarc J M Bonten
Jul 28, 2016·The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine·Federico Martinón-Torres
Oct 11, 2017·Annual Review of Cell and Developmental Biology·Katie L FlanaganSabra L Klein
Oct 12, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Yang YangIra M Longini
Dec 14, 2017·The New England Journal of Medicine·Lars OstergaardUNKNOWN B1971009 and B1971016 Trial Investigators
Sep 6, 2018·Therapeutic Advances in Vaccines and Immunotherapy·Paul Balmer, Laura J York

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00808028
NCT01830855
NCT01323270
NCT01461993
NCT01461980
NCT01352845
NCT01299480

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.